Cardiogeni

Cardiogeni is an early-stage biotechnology company focused on developing innovative regenerative therapies for cardiovascular diseases. The company leverages a proprietary mRNA-based delivery platform designed to stimulate the growth of new blood vessels and repair damaged heart tissue following ischemic events. Their lead programs focus on the localized delivery of vascular endothelial growth factor (VEGF) to treat conditions such as myocardial infarction and chronic heart failure. By utilizing transient mRNA expression, Cardiogeni aims to provide a safer and more controlled alternative to traditional viral gene therapies for cardiac regeneration.